Abstract
IntroductionThe INPULSIS® trials assessed the effects of nintedanib versus placebo in patients with IPF. Time to first investigator-reported acute exacerbation over 52 weeks was a key secondary endpoint. Adverse events...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have